Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors

Hong, Yun-Guang; Wen, Ruiting; Wu, Gang; Li, Shi; Liu, Wenxin; Chen, Zhanghui; Yang, Zhigang

doi:10.1016/j.intimp.2022.108821

Cited by 5 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sasso et al showed that a low-dose encapsulated gemcitabine formulation can selectively target M-MDSC subsets and reduce tumor-associated immunosuppression in the TME using the E.G7-OVA lymphoma model [ 124 ]. After TKI treatment of CML patients, the proportion of PMN-MDSCs and serum ARG1 and iNOS levels decreased significantly, with the proportion of effector NK cells increasing [ 125 ]. However, the treatment of CML with the TKI dasatinib resulted in a significant decrease in M-MDSCs [ 126 ].…”

Section: The Implications Of Mdscs In the Treatment Of Hematologic Ma...mentioning

confidence: 99%

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

Wang

Zhao

et al. 2023

Biomark Res

View full text Add to dashboard Cite

The immunosuppressive tumor microenvironment (TME) supports the development of tumors and limits tumor immunotherapy, including hematological malignancies. Hematological malignancies remain a major public health issue with high morbidity and mortality worldwide. As an important component of immunosuppressive regulators, the phenotypic characteristics and prognostic value of myeloid-derived suppressor cells (MDSCs) have received much attention. A variety of MDSC-targeting therapeutic approaches have produced encouraging outcomes. However, the use of various MDSC-targeted treatment strategies in hematologic malignancies is still difficult due to the heterogeneity of hematologic malignancies and the complexity of the immune system. In this review, we summarize the biological functions of MDSCs and further provide a summary of the phenotypes and suppressive mechanisms of MDSC populations expanded in various types of hematological malignancy contexts. Moreover, we discussed the clinical correlation between MDSCs and the diagnosis of malignant hematological disease, as well as the drugs targeting MDSCs, and focused on summarizing the therapeutic strategies in combination with other immunotherapies, such as various immune checkpoint inhibitors (ICIs), that are under active investigation. We highlight the new direction of targeting MDSCs to improve the therapeutic efficacy of tumors.

show abstract

Section: The Implications Of Mdscs In the Treatment Of Hematologic Ma...mentioning

confidence: 99%

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

Wang

Zhao

et al. 2023

Biomark Res

View full text Add to dashboard Cite

show abstract

“…found that ( 134 ) IM and DAS can both lower immune escape mechanisms by reducing the number of myeloid suppressor cells and the inhibitory factors arginase 1 (Arg1), Myeloperoxidase (MPO), and IL-10. According to researches, the proportion of Myeloid-derived suppressor cells (MDSC) and the blood concentrations of Arg1 and inducible nitric oxide synthase (iNOS) were both considerably higher in CML patients at diagnosis and significantly lower after TKI therapy ( 135 ). ZIYUAN LU et al.…”

Section: Immunometabolismmentioning

confidence: 99%

“…Previous studies indicated that patients with stable NK cell counts accompanied by higher cytotoxicity and increased killing capacity are more inclined to get sustained treatment-free survival ( 142 , 143 ). Previous study showed that following TKI treatment, the proportion of effector NK cells were increased ( 135 ). The results indicate that the number and killing capacity of NK cells may be utilized to further assess the risk of TKIs discontinuation.…”

Section: Immunometabolismmentioning

confidence: 99%

“…Lisa Christiansson et number of myeloid suppressor cells and the inhibitory factors arginase 1 (Arg1), Myeloperoxidase (MPO), and IL-10. According to researches, the proportion of Myeloid-derived suppressor cells (MDSC) and the blood concentrations of Arg1 and inducible nitric oxide synthase (iNOS) were both considerably higher in CML patients at diagnosis and significantly lower after TKI therapy (135). ZIYUAN LU et al found that (136) following treatment with a TKI (IM, DAS or NIL), Total T cells, Tregs (whose decline became more pronounced over time), CD4+ T cells, and CD8+ T cells all reduced to varying degrees in CML patients.…”

Section: Immunometabolismmentioning

confidence: 99%

See 1 more Smart Citation

Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review

Wen

Dong

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Incidence rates of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) are lower but more aggressive in children than in adults due to different biological and host factors. After the clinical application of tyrosine kinase inhibitor (TKI) blocking BCR/ABL kinase activity, the prognosis of children with CML and Ph+ ALL has improved dramatically. Yet, off-target effects and drug tolerance will occur during the TKI treatments, contributing to treatment failure. In addition, compared to adults, children may need a longer course of TKIs therapy, causing detrimental effects on growth and development. In recent years, accumulating evidence indicates that drug resistance and side effects during TKI treatment may result from the cellular metabolism alterations. In this review, we provide a detailed summary of the current knowledge on alterations in metabolic pathways including glucose metabolism, lipid metabolism, amino acid metabolism, and other metabolic processes. In order to obtain better TKI treatment outcomes and avoid side effects, it is essential to understand how the TKIs affect cellular metabolism. Hence, we also discuss the relevance of cellular metabolism in TKIs therapy to provide ideas for better use of TKIs in clinical practice.

show abstract

“…Se destacan otros inhibidores validados para las patologías hemato-oncológicas, incluyendo el ya mencionado Imatinib, además de Dasatinib, Nilotinib, Bosutinib, Ponatinib, Asciminib. [83] Genoma Humano…”

Section: Perfil Histórico Del Desarrollo Del Conocimiento De Las Vías...unclassified

Importancia de la ruta de señalización JAK/STAT en la sepsis

et al. 2022

View full text Add to dashboard Cite

El transductor de señal Janus-Kinasa y la vía de activación de la transcripción conocida como JAK/STAT es una ruta de señalización principal para la transducción de información en muchas citocinas inflamatorias implicadas durante la sepsis. Se ha demostrado que la vía JAK/STAT está fuertemente relacionada con el fallo multiorgánico, además que muchas citocinas pueden ejercer sus efectos biológicos a través de esta ruta. En los últimos años, se ha logrado un progreso significativo en la comprensión de las funciones de este complejo, sin embargo, su rol en la sepsis como objetivo terapéutico permanece en experimentación. En esta revisión se describen las funciones específicas de la vía JAK/STAT, su rol en la sepsis y presentamos un enfoque traslacional respecto a la perspectiva terapéutica para inhibir esta ruta de señalización durante la sepsis y su interacción con enfermedades inflamatorias como la COVID-19.

show abstract

Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors

Cited by 5 publications

References 29 publications

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review

Importancia de la ruta de señalización JAK/STAT en la sepsis

Contact Info

Product

Resources

About